Relationship between insulin resistance and endothelium-dependent vascular relaxation in patients with essential hypertension. 1997

Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
First Department of Internal Medicine, Hiroshima University School of Medicine, Japan.

The infusion of L-arginine induces the production of nitric oxide and stimulates the immediate secretion of insulin. To examine the relationship between insulin resistance and endothelium-dependent vascular relaxation in patients with essential hypertension, we evaluated the renal and insulin responses to L-arginine, 500 mg/kg infused intravenously over 30 minutes, in 23 patients with mild essential hypertension who were neither obese nor diabetic and in 20 normotensive control subjects. We found no difference between the two groups in blood glucose or insulin in the fasting condition. The renovascular relaxation induced by L-arginine was significantly less in patients with essential hypertension than in normotensive control subjects. The increase in plasma cyclic GMP in response to L-arginine was lower in hypertensive patients than in normotensive subjects. Although the serum concentrations of glucose in response to L-arginine were similar in the two groups, the serum insulin response of the essential hypertensives was significantly higher than that of the normotensive subjects. In all subjects, the peak cyclic GMP response to L-arginine was significantly correlated with the peak delta glucose/ delta insulin ratio response to L-arginine (r = .69, P < .001). Findings suggested that an impairment of endothelium-dependent renal vascular relaxation and a reduced sensitivity to insulin are present in patients with essential hypertension. A link may be present between the abnormality of the L-arginine/nitric oxide/cyclic GMP pathway and insulin resistance in patients with essential hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic

Related Publications

Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
July 1990, The New England journal of medicine,
Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
April 1993, Journal of the American College of Cardiology,
Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
May 1993, Circulation,
Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
December 1990, Deutsche medizinische Wochenschrift (1946),
Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
October 1992, Journal of the American Society of Nephrology : JASN,
Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
June 1986, Hypertension (Dallas, Tex. : 1979),
Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
April 1998, The Journal of clinical investigation,
Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
May 1993, Circulation,
Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
September 2003, Zhonghua yi xue za zhi,
Y Higashi, and T Oshima, and N Sasaki, and N Ishioka, and Y Nakano, and R Ozono, and M Yoshimura, and K Ishibashi, and H Matsuura, and G Kajiyama
July 1994, Clinical science (London, England : 1979),
Copied contents to your clipboard!